Vivos Therapeutics Inc, a medical technology company developing treatments for patients with obstructive sleep apnea (OSA) and snoring, signed a US nationwide agreement with Lincare, a supplier of in-home respiratory therapy products and services, for the distribution of Vivos’ oral appliances.
The agreement follows the conclusion of a distribution pilot with Lincare and furthers its efforts to collaborate with durable medical equipment (DME) companies in the US. Vivos granted Lincare six-month exclusivity to distribute certain designated Vivos devices.
“We are pleased to offer oral appliances as an alternative treatment to our non-compliant CPAP patients,” says Jeff Barnhard, CEO of Lincare, in a release. “Finding the best solutions for our sleep apnea patients has always been a high priority for Lincare. We look forward to working alongside Vivos-trained dentists.”
Kirk Huntsman, chairman and CEO of Vivos, says in a release, “Across the United States, hundreds of thousands of new CPAP units are rented or sold through DME companies each month. Lincare is one of the market leaders in this sector, and we are pleased to join forces with them in this pioneering initiative. It is well known that a sizable number of sleep apnea patients discontinue CPAP usage in search of alternative treatment options. This important collaboration between a national supplier of DME like Lincare and an innovative oral appliance company like Vivos will bring fresh solutions and relief to patients currently seeking alternatives.”
According to Huntsman, the pilot trial allowed both parties time to work through the program logistics, including the development of a new Vivos proprietary software to manage DME patients and scale to a national level.
Vivos is currently expanding the scope of its efforts with Lincare to the next five major markets. Additional markets will be added based on a rollout plan over the next six to 12 months, according to Huntsman in the release.